<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048942</url>
  </required_header>
  <id_info>
    <org_study_id>ON/2012/4234</org_study_id>
    <nct_id>NCT03048942</nct_id>
  </id_info>
  <brief_title>Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer</brief_title>
  <acronym>CONCEPT</acronym>
  <official_title>A Randomised Phase II Pilot Study of 3 Weekly Cabazitaxel Versus Weekly Paclitaxel Chemotherapy in the First Line Treatment of HER2 Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Bristol NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of
      chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly
      Paclitaxel to determine the difference in progression free survival between the 2 groups. If
      results at that stage suggest a potential benefit then the trial will be developed further to
      accrue 70 more patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective multicentre, randomised, open label, study comparing the efficacy and
      the safety of six 3-weekly cycles cabazitaxel versus 18 x weekly paclitaxel given as first
      line chemotherapy treatment in patients with HER2-normal metastatic breast cancer.
      Randomisation will be conducted by a 1:1 ratio.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Defined as the time from randomisation to either disease progression or death from any cause, whichever came first, assessed up to 5 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>At the completion of 6 cycles of chemotherapy, which is after 18 weeks</time_frame>
    <description>Defined as stable disease rate + partial response rate+complete response rate according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At completion of 6 cycles of chemotherapy, which is after 18 weeks.</time_frame>
    <description>Defined as complete and partial response recorded from the start of treatment to completion of 6 cycles of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Determined as the time from randomisation to death from any cause. Average survival rates for this population may be approximately 18 months.</time_frame>
    <description>Survival duration from randomisation to date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next chemotherapy treatment</measure>
    <time_frame>Measured from from the date of the last day of trial treatment. approximately after progression which on average would be after 12 months.</time_frame>
    <description>time from randomisation to another chemotherapy treatment after confirmed progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Determined by time from randomisation to radiological partial response, usually within the 6 cycles of treatment, therefore wihtin 18 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>EQ5D-5L and FACT B will be completed at baseline, prior to cycles 3 and 5 and at the end of treatment visit, therefore within approximately 21 weeks from randomisation</time_frame>
    <description>2 Quality of life questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events and Number of participants with adverse events per arm and the grade of AEs</measure>
    <time_frame>Form the date of consent to 30 days after trial treatment has stopped.</time_frame>
    <description>CTCAE Version 4.0 graded AEs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>HER2 Negative Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cycles of cabazitaxel intravenous chemotherapy 25mg/m2 on day 1 of each 21 day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 cycles of Paclitaxel intravenous chemotherapy 80mg/m2 on days 1,8 and 15 of each 21 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>3 weekly cyctotoxic chemotherapy</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jevtana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Weekly cyctotoxic chemotherapy</description>
    <arm_group_label>Paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Metastatic breast cancer fit to receive cytotoxic chemotherapy for metastatic disease

          -  Measurable disease as per RECIST 1.1

          -  HER2 negative defined as ICH 0+, 1+ or 2+ and FISH/SISH/CISH(ration&lt;2.0) in the case
             of IHC 2+

          -  ECOG performance status 0 or 1

          -  ER+ve or ER-ve

          -  Female age ≥18 years

          -  Anticipated life expectancy &gt; 6 months

          -  Haemoglobin &gt;10.0g/DL

          -  Absolute neutrophil count&gt;1.5 x 10^9/L

          -  Platelet count&gt;100 x 10^9/L

          -  ALT/SGPT&lt;1.5 X ULN

          -  Serum creatinine &lt;1.5 x ULN

          -  Negative pregnancy test for all women of child bearing potential

        Exclusion Criteria:

          -  Grade ≥2 oral mucositis or peripheral or sensory neuropathy

          -  History of other malignancy

          -  History of severe hypersensitivity ≥grade 3 to polysorbate 80- containing drugs and
             taxanes

          -  Clinically significant cardiovascular disease

          -  Any acute or chronic medical condition

          -  Acute infection requiring systemic antibiotics or antifungal medication

          -  Sex hormones

          -  Administration of any live vaccine within 8 weeks

          -  Concurrent or planned treatment with strong inhibitors or strong inducers of
             cytochrome P450 3A4/5

          -  Participation in another clinical trial with an investigational drug within 30 days of
             randomisation

          -  Pregnant or breast feeding women

          -  Contraindications to the use of corticosteroid treatment

          -  HER2 Positive breast cancer

          -  Previous Paclitaxel chemotherapy in the adjuvant setting

          -  Previous cytotoxic chemotherapy for metastatic disease

          -  Palliative radiotherapy for metastatic disease within 4 weeks of randomisation

          -  Symptomatic brain metastases confirmed with CT/MRI brain

          -  History of other malignancy

          -  Grade 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit K Bahl</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Bristol NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit K Bahl</last_name>
    <phone>0117 342 2418</phone>
    <email>amit.bahl@uhbristol.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alicia Bravo</last_name>
    <email>alicia.bravo@uhbristol.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Imperial Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <state>Avon</state>
        <zip>bs3 1ta</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shola Ogegbo</last_name>
      <email>shola.ogegbo@imperial.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Allen</last_name>
      <email>tania.allen1@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre, Horfield Road</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Hunt</last_name>
      <phone>0117 342 7857</phone>
      <email>nicholas.hunt@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Amit K Bahl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kizzy Baines</last_name>
      <phone>01932 402865</phone>
      <email>kizzy.baines@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Hospital, Nottingham</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Tasker</last_name>
      <email>carol.tasker@nuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>helen smith</last_name>
      <email>helensmith23@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall and Treliske</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Goddard</last_name>
      <email>caroline.goddard@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worcestershire Acute Hospitals NHS Trust</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayne tyler</last_name>
      <email>jaynetyler@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Cabazitaxel</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

